Personal information

Verified email domains

Biography

I have been an NHS consultant gastroenterologist at Cambridge University Hospital since 2001. I was appointed as director of the Cambridge Biomedical Research Centre and awarded an honorary chair by the University of Cambridge in 2020. My clinical and research interests are in Crohn’s disease and ulcerative colitis (collectively inflammatory bowel disease or IBD). I am recognised as one of the leading global investigators in IBD pathogenesis and particularly IBD genetics. According to Google Scholar my H index is 80 with >27,000 citations from 34 publications in the last 5 years. Ten of the papers on which I have played a key role have over 1000 citations, including one on which I was first author (1395 citations) and another the senior author (3100 citations).

IBD exacts a huge toll on patients’ lives and NHS budgets. Improved treatment outcomes require better understanding of IBD pathogenic pathways and determinants of severity. My research aims to identify these; and target them for clinical benefit.

My basic training in IBD genetics occurred in Oxford at the Wellcome Trust Centre for Human Genetics where I undertook a 3.5 year MRC research training fellowship supervised by John Bell and Derek Jewell. I moved to Cambridge in 2001 and established the East of England IBD genetics research programme. I founded and have led the UK IBD genetics consortium for 15 years, and was co-PI and management committee member for the Wellcome Trust Case Control Consortium. These collaborations led to seminal early GWAS studies in Crohn's disease (WTCCC, Nature 2007; Parkes et al, Nature Genetics 2007).

With regard to ulcerative colitis we provided the first detailed insights into the molecular genetic overlap between ulcerative colitis and Crohn's disease (Fisher et al, Nature Genetics 2008). With WTCCC we subsequently undertook a full GWAS in UC (Barrett et al, Nature Genetics 2009). GWAS remains a key technology by which we identify new IBD pathogenic pathways (de Lange et al Nature Genetics 2017) although increasingly we are using whole genome or whole exome sequencing in our studies (Luo et al Nature Genetics 2017).

In 2007, with other group leaders from the UK, North America and Europe, I founded the international IBD genetics consortium and chaired this group for its first 3 years. During this period we published 3 reports in Nature Genetics (Barrett et al, 2008; Franke et al, 2010 and Anderson et al, 2011) and laid the groundwork for the Immunochip study in which we genotyped >40,000 patients with IBD and identified 163 independent genome-wide significant loci (Jostins et al, Nature 2012). Additional publications have followed in Nature, Nature Genetics and the Lancet.

Collaborating with Ken Smith I helped in the development of an accurate biomarker of IBD prognosis based on gene expression profiling in CD8+ T cells (Lee et al, JCI 2011). The genetic variants underlying the signature have been functionally interrogated (Lee et al, Cell 2015). This has been developed for a biomarker-stratified trial in early Crohn's disease - the first stratified medicine trial in inflammatory disease - funded by the Wellcome Trust. I am national Chief Investigator for this study. Also playing to the theme of stratified medicine in Crohn’s disease, we have recently identified a number of loci associated with disease course / prognosis as opposed to disease susceptibility (Lee et al, Nature Genetics 2017).

I have collaborated on a number of studies investigating the role of the microbiota in IBD, with investigators in the US and UK – published in Cell (2015) and recently in Immunity (2019) and Gut Microbes (2019). We have recently been awarded a $1.4 million NIH grant to continue work on the virome in IBD.

I am Chief Investigator for the national IBD BioResource, funded by the MRC and NIHR. Since 2016 we have recruited >34,000 patients with IBD who can be recalled by phenotype or genotype for downstream studies (Parkes Gut 2019; Stournaras et al Gut 2021). Recently we have been awarded a £4.5 million UKRI grant to align routinely collected healthcare data to the NIHR IBD Bioresource, and to make the whole available to the research community. Among the many studies the IBD BioResource is supporting is a pharmacogenetics analysis identifying genetic markers of immunogenicity to anti-TNF therapy – likely to have an early clinical impact on IBD management (Sazonovs et al Gastroenterology 2019).

In 2014 I was elected as the first chair of the British Society of Gastroenterology IBD Clinical Research Group to drive translational IBD research UK-wide. During my 3 year chairmanship we increased MRC/WT/NIHR funding of UK IBD studies from £1.2 million in the previous 5 years to £14.8 million across 5 sites. I am still a member of that committee and also of the Research Advisory Group at Crohn’s and Colitis UK.

Activities

Employment (1)

Cambridge University Hospitals: Cambridge, GB

2001-08-01 to present | Professor
Employment
Source: Self-asserted source
Miles Parkes

Education and qualifications (3)

University of Oxford: Oxford, GB

1996 to 1999 | MRC Clinical Training Fellow (DM Medicine)
Qualification
Source: Self-asserted source
Miles Parkes

Imperial College London: London, Westminster, GB

1987 to 1990 (MBBS Medicine)
Qualification
Source: Self-asserted source
Miles Parkes

University of Oxford: Oxford, GB

1984 to 1987 | BA (Physiology for Medicine)
Education
Source: Self-asserted source
Miles Parkes

Professional activities (5)

University of Oxford: Oxford, GB

BA 1st Class (Physiology for Medicine)
Distinction
Source: Self-asserted source
Miles Parkes

European Crohn's and Colitis Organisation: Vienna, AT

Membership
Source: Self-asserted source
Miles Parkes

British Society of Gastroenterology: London, GB

Membership
Source: Self-asserted source
Miles Parkes

University of Cambridge: Cambridge, GB

2020 to present | Professor of Translational Gastroenterology
Invited position
Source: Self-asserted source
Miles Parkes

Academy of Medical Sciences: London, GB

2022-12-15 | FMedSci
Distinction
Source: Self-asserted source
Miles Parkes

Funding (14)

'The UK Inflammatory Bowel Disease (IBD) Bioresource’

2020-09 to 2025-08 | Grant
Crohn's and Colitis UK (St Albans, GB)
GRANT_NUMBER: M2020/1
Source: Self-asserted source
Miles Parkes

The UK IBD BioResource: Translating today’s science into tomorrow’s treatments in Crohn’s disease

2020-09 to 2023-08 | Grant
Leona M. and Harry B. Helmsley Charitable Trust (NY, NY, US)
GRANT_NUMBER:

G-2002-04255

Source: Self-asserted source
Miles Parkes

Gut Reaction - The Health Data Research Hub for Inflammatory Bowel Disease

2019-09-30 to 2022-08-30 | Grant
Medical Research Council (London, GB)
GRANT_NUMBER: MC_PC_19003
Source: Self-asserted source
Miles Parkes via DimensionsWizard

The role of clonal haematopoiesis in immune-mediated inflammatory diseases

2019-06-30 to 2020-12-31 | Grant
Medical Research Council (London, GB)
GRANT_NUMBER: MR/T004231/1
Source: Self-asserted source
Miles Parkes via DimensionsWizard

Single cell transcriptome analysis in IBD

2019 to present | Grant
Open Targets (Cambridge, GB)
Source: Self-asserted source
Miles Parkes

Genotype-stratified response to Tofacitinib in UC

2019 to 2023 | Grant
Pfizer (NY, NY, US)
Source: Self-asserted source
Miles Parkes

Computational and Experimental Resources for Virome analysis in IBD

2019 to 2022 | Grant
National Institutes of Health (Md., Md., US)
Source: Self-asserted source
Miles Parkes

Personalised Therapy in Crohn's Disease

2017-12-11 to 2021-12-10 | Grant
Wellcome Trust (London, GB)
GRANT_NUMBER:

200448/Z/16/Z

Source: Self-asserted source
Miles Parkes via DimensionsWizard

The Virome of Inflammatory Bowel Disease

2015-10-01 to 2018-09-30 | Grant
Crohn's and Colitis Foundation (New York, US)
GRANT_NUMBER:

361650

Source: Self-asserted source
Miles Parkes via DimensionsWizard

The UK Inflammatory Bowel Disease Bioresource: Progressing from Genetics to Function and Clinical Translation in Crohn's Disease & Ulcerative Colitis

2015-08-31 to 2021-08-30 | Grant
Medical Research Council (London, GB)
GRANT_NUMBER: MR/M00533X/1
Source: Self-asserted source
Miles Parkes via DimensionsWizard

A BIOMARKER AND PATHWAY DISCOVERY PROGRAMME IN INFLAMMATORY DISEASE

2014-04-30 to 2020-03-01 | Grant
Medical Research Council (London, GB)
GRANT_NUMBER: MR/L019027/1
Source: Self-asserted source
Miles Parkes via DimensionsWizard

Personalised therapy in Crohn's disease- a biomarker-stratified trail

2013-05-18 to 2015-07-17 | Grant
Wellcome Trust (London, GB)
GRANT_NUMBER:

099450/Z/12/Z

Source: Self-asserted source
Miles Parkes via DimensionsWizard

Genome-wide association scan in ulcerative colitis: characterizing genetic determinants of susceptibility and disease phenotype.

2008-06-16 to 2010-12-15 | Grant
Wellcome Trust (London, GB)
GRANT_NUMBER:

084725/Z/08/Z

Source: Self-asserted source
Miles Parkes via DimensionsWizard

Defining the genetic architecture of Crohn's Disease.

2007-08-01 to 2008-01-31 | Grant
Wellcome Trust (London, GB)
GRANT_NUMBER:

076113/B/04/A

Source: Self-asserted source
Miles Parkes via DimensionsWizard

Works (50 of 172)

Items per page:
Page 1 of 4

Assessing ‘response’ to the low-FODMAP diet in irritable bowel syndrome: Should we be reporting harder primary endpoints?

Clinical Nutrition
2024-05 | Journal article
Contributors: Thomas Edward Conley; Miles Parkes; Stephen Moss; Chris Probert
Source: check_circle
Crossref

Moving towards more patient-centred clinical trials in IBD.

Nature reviews. Gastroenterology & hepatology
2021-07 | Journal article
Contributors: Noor NM; Parkes M; Raine T
Source: Self-asserted source
Miles Parkes via Europe PubMed Central

A Crohn's disease-associated IL2RA enhancer variant determines the balance of T cell immunity by regulating responsiveness to IL-2 signaling.

Journal of Crohn's & colitis
2021-06 | Journal article
Contributors: Goldberg R; Clough JN; Roberts LB; Sanchez J; Kordasti S; Petrov N; Hertweck A; Lorenc A; Jackson I; Tasker S et al.
Source: Self-asserted source
Miles Parkes via Europe PubMed Central

Sequencing of over 100,000 individuals identifies multiple genes and rare variants associated with Crohns disease susceptibility

2021-06 | Preprint
Contributors: Sazonovs A; Stevens CR; Venkataraman GR; Yuan K; Avila B; Abreu MT; Ahmad T; Allez M; Ananthakrishnan AN; Atzmon G et al.
Source: Self-asserted source
Miles Parkes via Europe PubMed Central

OP17 Impact of phenotypic and genetic factors on Crohn’s Disease evolution in a cohort of 13,926 patients

Journal of Crohn's and Colitis
2021-05 | Journal article
Part of ISSN: 1873-9946
Part of ISSN: 1876-4479
Source: Self-asserted source
Miles Parkes

The Impact of NOD2 Genetic Variants on the Gut Mycobiota in Crohn's Disease Patients in Remission and Individuals Without Gastrointestinal Inflammation.

Journal of Crohn's & colitis
2021-05 | Journal article
Source: Self-asserted source
Miles Parkes
grade
Preferred source (of 4)‎

Two microbiota subtypes identified in Irritable Bowel Syndrome with distinct responses to the low-FODMAP diet

2021-05 | Preprint
Contributors: Vervier K; Moss S; Kumar N; Adoum A; Barne M; Browne H; Kaser A; Kiely C; Neville A; Powell N et al.
Source: Self-asserted source
Miles Parkes via Europe PubMed Central

DOP07 Ulcerative Colitis associated single nucleotide polymorphisms found in transcription factor binding sites effect key pathogenesis pathways and facilitate patient stratification

Journal of Crohn's and Colitis
2021-05-27 | Journal article
Part of ISSN: 1873-9946
Part of ISSN: 1876-4479
Source: Self-asserted source
Miles Parkes

Enhanced neoplasia detection in chronic ulcerative colitis: the ENDCaP-C diagnostic accuracy study

2021-01 | Book
Contributors: Awasthi A; Barbour J; Beggs A; Bhandari P; Blakeway D; Brookes M; Brown J; Brown M; Caldwell G; Clokie S et al.
Source: Self-asserted source
Miles Parkes via Europe PubMed Central

SARS-CoV-2 vaccination for patients with inflammatory bowel disease: a British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group position statement

The Lancet Gastroenterology and Hepatology
2021-01 | Journal article
EID:

2-s2.0-85100603177

Part of ISSN: 24681253
Source: Self-asserted source
Miles Parkes
grade
Preferred source (of 2)‎

Thiopurine monotherapy is effective in ulcerative colitis but significantly less so in Crohn’s disease: long-term outcomes for 11 928 patients in the UK inflammatory bowel disease bioresource

Gut
2020-10 | Journal article
Source: Self-asserted source
Miles Parkes
grade
Preferred source (of 4)‎

Randomized Trial of Ciprofloxacin Doxycycline and Hydroxychloroquine Versus Budesonide in Active Crohn’s Disease

Digestive diseases and sciences
2020-07 | Journal article
Source: Self-asserted source
Miles Parkes
grade
Preferred source (of 2)‎

Somatic evolution in non-neoplastic IBD-affected colon

Cell
2020-07 | Journal article
Source: Self-asserted source
Miles Parkes
grade
Preferred source (of 2)‎

Clinical Trials [and Tribulations]: The Immediate Effects of COVID-19 on IBD Clinical Research Activity in the UK

Journal of Crohn's and Colitis
2020-06 | Journal article
Source: Self-asserted source
Miles Parkes
grade
Preferred source (of 2)‎

British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic

Gut
2020-04 | Journal article
Source: Self-asserted source
Miles Parkes
grade
Preferred source (of 2)‎

Somatic mosaicism and common genetic variation contribute to the risk of very-early-onset inflammatory bowel disease

Nature communications
2020-02 | Journal article
Source: Self-asserted source
Miles Parkes
grade
Preferred source (of 2)‎

Effectiveness and safety of vedolizumab in inflammatory bowel disease patients aged 60 and over: an observational multicenter UK experience

Annals of gastroenterology
2020-01 | Journal article
Source: Self-asserted source
Miles Parkes
grade
Preferred source (of 2)‎

Personalised medicine in Crohn's disease

The Lancet Gastroenterology & Hepatology
2020-01 | Journal article
Source: Self-asserted source
Miles Parkes
grade
Preferred source (of 2)‎

Association of genetic variants in NUDT15 with thiopurine-induced myelosuppression in patients with inflammatory bowel disease

Jama
2019 | Journal article
Source: Self-asserted source
Miles Parkes

Association of Genetic Variants in NUDT15 with Thiopurine-Induced Myelosuppression in Patients with Inflammatory Bowel Disease

JAMA - Journal of the American Medical Association
2019 | Journal article
EID:

2-s2.0-85062067665

Part of ISSN: 15383598 00987484
Contributors: Walker, G.J.; Harrison, J.W.; Heap, G.A.; Voskuil, M.D.; Andersen, V.; Anderson, C.A.; Ananthakrishnan, A.N.; Barrett, J.C.; Beaugerie, L.; Bewshea, C.M. et al.
Source: Self-asserted source
Miles Parkes via Scopus - Elsevier

Autologous stem cell transplantation in refractory Crohn's disease - Low intensity therapy evaluation (ASTIClite): Study protocols for a multicentre, randomised controlled trial and observational follow up study

BMC Gastroenterology
2019 | Journal article
EID:

2-s2.0-85066508175

Part of ISSN: 1471230X
Contributors: Snowden, J.A.; Hawkey, C.; Hind, D.; Swaby, L.; Mellor, K.; Emsley, R.; Mandefield, L.; Lee, E.; Badoglio, M.; Polge, E. et al.
Source: Self-asserted source
Miles Parkes via Scopus - Elsevier

British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults

Gut
2019 | Journal article
EID:

2-s2.0-85070056729

Part of ISSN: 14683288
Contributors: Lamb, C.A.; Kennedy, N.A.; Raine, T.; Hendy, P.A.; Smith, P.J.; Limdi, J.K.; Hayee, B.; Lomer, M.C.E.; Parkes, G.C.; Selinger, C. et al.
Source: Self-asserted source
Miles Parkes via Scopus - Elsevier

Diverticular disease: Picking pockets and population biobanks

Gut
2019 | Journal article
EID:

2-s2.0-85062346023

Part of ISSN: 14683288 00175749
Contributors: Weersma, R.K.; Parkes, M.
Source: Self-asserted source
Miles Parkes via Scopus - Elsevier

IBD BioResource: An open-access platform of 25 000 patients to accelerate research in Crohn's and Colitis

Gut
2019 | Journal article
EID:

2-s2.0-85068560410

Part of ISSN: 14683288 00175749
Contributors: Parkes, M.
Source: Self-asserted source
Miles Parkes via Scopus - Elsevier
grade
Preferred source (of 2)‎

IBD genomic risk loci and overlap with other inflammatory diseases

Molecular Genetics of Inflammatory Bowel Disease
2019 | Book chapter
EID:

2-s2.0-85098920046

Contributors: Hadizadeh, F.; Lees, C.W.; Labbé, C.; Rioux, J.D.; Parkes, M.; Zhernakova, A.; Franke, A.; Hedin, C.; D'Amato, M.
Source: Self-asserted source
Miles Parkes via Scopus - Elsevier

Microscopic colitis

Medicine (United Kingdom)
2019 | Journal article
EID:

2-s2.0-85066090750

Part of ISSN: 13654357 13573039
Contributors: Parkes, M.
Source: Self-asserted source
Miles Parkes via Scopus - Elsevier

Mitochondrial neurogastrointestinal encephalopathy: A clinicopathological mimic of Crohn's disease

BMC Gastroenterology
2019 | Journal article
EID:

2-s2.0-85059986745

Part of ISSN: 1471230X
Contributors: Patel, R.; Coulter, L.L.; Rimmer, J.; Parkes, M.; Chinnery, P.F.; Swift, O.
Source: Self-asserted source
Miles Parkes via Scopus - Elsevier

Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study

The Lancet Gastroenterology and Hepatology
2019 | Journal article
EID:

2-s2.0-85063131044

Part of ISSN: 24681253
Contributors: Kennedy, N.A.; Heap, G.A.; Green, H.D.; Hamilton, B.; Bewshea, C.; Walker, G.J.; Thomas, A.; Nice, R.; Perry, M.H.; Bouri, S. et al.
Source: Self-asserted source
Miles Parkes via Scopus - Elsevier

Trial summary and protocol for a phase II randomised placebo-controlled double-blinded trial of Interleukin 1 blockade in Acute Severe Colitis: The IASO trial

BMJ Open
2019 | Journal article
EID:

2-s2.0-85061699210

Part of ISSN: 20446055
Contributors: Thomas, M.G.; Bayliss, C.; Bond, S.; Dowling, F.; Galea, J.; Jairath, V.; Lamb, C.; Probert, C.; Timperley-Preece, E.; Watson, A. et al.
Source: Self-asserted source
Miles Parkes via Scopus - Elsevier

Comparative performances of machine learning methods for classifying Crohn Disease patients using genome-wide genotyping data

Scientific Reports
2019-12 | Journal article
Part of ISSN: 2045-2322
Source: Self-asserted source
Miles Parkes
grade
Preferred source (of 2)‎

A blood-based prognostic biomarker in IBD

Gut
2019-10 | Journal article
Source: Self-asserted source
Miles Parkes
grade
Preferred source (of 2)‎

HLA-DQA1* 05 carriage associated with development of anti-drug antibodies to infliximab and adalimumab in patients with Crohn’s disease

Gastroenterology
2019-10 | Journal article
Source: Self-asserted source
Miles Parkes
grade
Preferred source (of 3)‎

Dynamic immunoglobulin responses to gut bacteria during inflammatory bowel disease

Gut microbes
2019-06 | Journal article
Source: Self-asserted source
Miles Parkes
grade
Preferred source (of 2)‎

Anti-commensal IgG Drives Intestinal Inflammation and Type 17 Immunity in Ulcerative Colitis

Immunity
2019-03 | Journal article
EID:

2-s2.0-85064143585

Part of ISSN: 10974180 10747613
Source: Self-asserted source
Miles Parkes
grade
Preferred source (of 2)‎

Acetarsol Suppositories: Effective Treatment for Refractory Proctitis in a Cohort of Patients with Inflammatory Bowel Disease

Digestive Diseases and Sciences
2018 | Journal article
EID:

2-s2.0-85044033825

Part of ISSN: 15732568 01632116
Contributors: Kiely, C.J.; Clark, A.; Bhattacharyya, J.; Moran, G.W.; Lee, J.C.; Parkes, M.
Source: Self-asserted source
Miles Parkes via Scopus - Elsevier

Debate session: So what causes inflammatory bowel disease? It's all in the genes

Journal of Gastroenterology and Hepatology (Australia)
2018 | Journal article
EID:

2-s2.0-85052819059

Part of ISSN: 14401746 08159319
Contributors: Parkes, M.
Source: Self-asserted source
Miles Parkes via Scopus - Elsevier

IBD risk loci are enriched in multigenic regulatory modules encompassing putative causative genes

Nature Communications
2018 | Journal article
EID:

2-s2.0-85048925642

Part of ISSN: 20411723
Contributors: Momozawa, Y.; Dmitrieva, J.; Théâtre, E.; Deffontaine, V.; Rahmouni, S.; Charloteaux, B.; Crins, F.; Docampo, E.; Elansary, M.; Gori, A.-S. et al.
Source: Self-asserted source
Miles Parkes via Scopus - Elsevier

Insights into the genetic epidemiology of Crohn's and rare diseases in the Ashkenazi Jewish population

PLoS Genetics
2018 | Journal article
EID:

2-s2.0-85048235952

Part of ISSN: 15537404 15537390
Contributors: Rivas, M.A.; Avila, B.E.; Koskela, J.; Huang, H.; Stevens, C.; Pirinen, M.; Haritunians, T.; Neale, B.M.; Kurki, M.; Ganna, A. et al.
Source: Self-asserted source
Miles Parkes via Scopus - Elsevier

Multiomics Analyses to Deliver the Most Effective Treatment to Every Patient With Inflammatory Bowel Disease

Gastroenterology
2018 | Journal article
EID:

2-s2.0-85055839608

Part of ISSN: 15280012 00165085
Contributors: Weersma, R.K.; Xavier, R.J.; Weersma, R.K.; Barrett, J.C.; Vermeire, S.; Xavier, R.J.; Anderson, C.A.; Wijmenga, C.; Daly, M.J.; Alm, E.J. et al.
Source: Self-asserted source
Miles Parkes via Scopus - Elsevier

NOX1 loss-of-function genetic variants in patients with inflammatory bowel disease

Mucosal Immunology
2018 | Journal article
EID:

2-s2.0-85042175251

Part of ISSN: 19353456 19330219
Contributors: Schwerd, T.; Bryant, R.V.; Pandey, S.; Capitani, M.; Meran, L.; Cazier, J.-B.; Jung, J.; Mondal, K.; Parkes, M.; Mathew, C.G. et al.
Source: Self-asserted source
Miles Parkes via Scopus - Elsevier

On the threshold of personalized medicine in inflammatory bowel disease: Next generation genetic predictors

Journal of Gastroenterology and Hepatology (Australia)
2018 | Journal article
EID:

2-s2.0-85052792119

Part of ISSN: 14401746 08159319
Contributors: Parkes, M.
Source: Self-asserted source
Miles Parkes via Scopus - Elsevier

Patients with perianal Crohn's fistulas experience delays in accessing anti-TNF therapy due to slow recognition, diagnosis and integration of specialist services: lessons learned from three referral centres

Colorectal Disease
2018 | Journal article
EID:

2-s2.0-85044744319

Part of ISSN: 14631318 14628910
Contributors: Lee, M.J.; Freer, C.; Adegbola, S.; Elkady, S.; Parkes, M.; Hart, A.; Fearnhead, N.S.; Lobo, A.J.; Brown, S.R.
Source: Self-asserted source
Miles Parkes via Scopus - Elsevier

PRedicting Outcomes for Crohn's dIsease using a moLecular biomarkEr (PROFILE): Protocol for a multicentre, randomised, biomarker-stratified trial

BMJ Open
2018 | Journal article
EID:

2-s2.0-85058233768

Part of ISSN: 20446055
Contributors: Parkes, M.; Noor, N.M.; Dowling, F.; Leung, H.; Bond, S.; Whitehead, L.; Upponi, S.; Kinnon, P.; Sandham, A.P.; Lyons, P.A. et al.
Source: Self-asserted source
Miles Parkes via Scopus - Elsevier

Selectively targeting the gut in inflammatory bowel disease: Targeting integrins

Journal of Gastroenterology and Hepatology (Australia)
2018 | Journal article
EID:

2-s2.0-85052794145

Part of ISSN: 14401746 08159319
Contributors: Parkes, M.
Source: Self-asserted source
Miles Parkes via Scopus - Elsevier

The impact of NOD2 variants on fecal microbiota in Crohn's disease and controls without gastrointestinal disease

Inflammatory Bowel Diseases
2018 | Journal article
EID:

2-s2.0-85050148688

Part of ISSN: 15364844 10780998
Contributors: Kennedy, N.A.; Lamb, C.A.; Berry, S.H.; Walker, A.W.; Mansfield, J.; Parkes, M.; Simpkins, R.; Tremelling, M.; Nutland, S.; Parkhill, J. et al.
Source: Self-asserted source
Miles Parkes via Scopus - Elsevier

Defective ATG16L1-mediated removal of IRE1α drives Crohn's disease-like ileitis

Journal of Experimental Medicine
2017 | Journal article
EID:

2-s2.0-85012261819

Part of ISSN: 15409538 00221007
Contributors: Tschurtschenthaler, M.; Adolph, T.E.; Ashcroft, J.W.; Niederreiter, L.; Bharti, R.; Saveljeva, S.; Bhattacharyya, J.; Flak, M.B.; Shih, D.Q.; Fuhler, G.M. et al.
Source: Self-asserted source
Miles Parkes via Scopus - Elsevier

Exploring the genetic architecture of inflammatory bowel disease by whole-genome sequencing identifies association at ADCY7

Nature Genetics
2017 | Journal article
EID:

2-s2.0-85008626255

Part of ISSN: 15461718 10614036
Contributors: Luo, Y.; De Lange, K.M.; Jostins, L.; Moutsianas, L.; Randall, J.; Kennedy, N.A.; Lamb, C.A.; McCarthy, S.; Ahmad, T.; Edwards, C. et al.
Source: Self-asserted source
Miles Parkes via Scopus - Elsevier

Fine-mapping inflammatory bowel disease loci to single-variant resolution

Nature
2017 | Journal article
EID:

2-s2.0-85024387670

Part of ISSN: 14764687 00280836
Contributors: Huang, H.; Fang, M.; Jostins, L.; Umićević Mirkov, M.; Boucher, G.; Anderson, C.A.; Andersen, V.; Cleynen, I.; Cortes, A.; Crins, F. et al.
Source: Self-asserted source
Miles Parkes via Scopus - Elsevier

Genome-wide association study identifies distinct genetic contributions to prognosis and susceptibility in Crohn's disease

Nature Genetics
2017 | Journal article
EID:

2-s2.0-85008689993

Part of ISSN: 15461718 10614036
Contributors: Lee, J.C.; Biasci, D.; Roberts, R.; Gearry, R.B.; Mansfield, J.C.; Ahmad, T.; Prescott, N.J.; Satsangi, J.; Wilson, D.C.; Jostins, L. et al.
Source: Self-asserted source
Miles Parkes via Scopus - Elsevier

Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease

Nature Genetics
2017 | Journal article
EID:

2-s2.0-85008712412

Part of ISSN: 15461718 10614036
Contributors: De Lange, K.M.; Moutsianas, L.; Lee, J.C.; Lamb, C.A.; Luo, Y.; Kennedy, N.A.; Jostins, L.; Rice, D.L.; Gutierrez-Achury, J.; Ji, S.-G. et al.
Source: Self-asserted source
Miles Parkes via Scopus - Elsevier
Items per page:
Page 1 of 4